Analysts’ Recent Ratings Changes for Novo Nordisk A/S (NVO)

Novo Nordisk A/S (NYSE: NVO) has recently received a number of price target changes and ratings updates:

• 10/12/2026 – Novo Nordisk A/S was given a new $40.00 price target by BMO Capital Markets. They now have a “market perform” rating on the stock.
• 10/9/2026 – Novo Nordisk A/S had its “neutral” rating reaffirmed by Citigroup Inc..
• 10/8/2026 – Novo Nordisk A/S was downgraded by Weiss Ratings from “hold (c-)” to “sell (d+)”.
• 9/29/2026 – Novo Nordisk A/S had its “market perform” rating reaffirmed by BMO Capital Markets.
• 9/29/2026 – Novo Nordisk A/S had its “sell” rating reaffirmed by Deutsche Bank Aktiengesellschaft.
• 9/22/2026 – Novo Nordisk A/S was downgraded by Cfra from “hold” to “sell”. They now have a $38.00 price target on the stock.
• 9/21/2026 – Novo Nordisk A/S had its “neutral” rating reaffirmed by Jefferies Financial Group Inc..
• 9/21/2026 – Novo Nordisk A/S had its “neutral” rating reaffirmed by JPMorgan Chase & Co..
• 9/21/2026 – Novo Nordisk A/S had its “neutral” rating reaffirmed by UBS Group AG.
• 9/21/2026 – Novo Nordisk A/S had its “neutral” rating reaffirmed by Berenberg Bank.
• 9/10/2026 – Novo Nordisk A/S had its “hold” rating reaffirmed by HSBC Holdings plc.
• 9/7/2026 – Novo Nordisk A/S had its “neutral” rating reaffirmed by Barclays PLC.
• 8/27/2026 – Novo Nordisk A/S was downgraded by Deutsche Bank Aktiengesellschaft from “hold” to “sell”.

Novo Nordisk A/S Cuts Dividend

The firm also recently announced a dividend, which was paid on Tuesday, August 25th. Stockholders of record on Monday, August 17th were paid a dividend of $0.5786 per share. This represents a dividend yield of 258.0%. This is a drop from Novo Nordisk A/S’s previous dividend of $1.2751. The ex-dividend date of this dividend was Monday, August 17th. Novo Nordisk A/S’s payout ratio is presently 20.05%.

Novo Nordisk A/S is a Danish pharmaceutical company headquartered in Bagsværd, Denmark. The company focuses on developing and manufacturing medicines and delivery systems for chronic diseases, with a primary emphasis on diabetes and obesity care.

Novo Nordisk offers a broad portfolio of insulin products, as well as glucagon-like peptide-1 (GLP-1) medicines used in diabetes management and weight treatment. Its well-known products include Ozempic and Rybelsus for type 2 diabetes, Wegovy for chronic weight management, and several modern and human insulin products.